News

The once-daily nucleotide sofosbuvir plus ribavirin (RBV) was assessed in FISSION study while sofosbuvir plus ribavirin and pegylated interferon was assessed in NEUTRINO study in chronic HCV infected

The GOBIOM database assists FDA in its biomarker qualification process by providing most recent information on all the clinically evaluated, exploratory and preclinical biomarkers reported in a range

The firm’s ADCETRIS is the first in a new class of antibody-drug conjugates (ADCs) used for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic

The decree was signed by US District Court for the Northern District judge Lesley Wells of Ohio on 31 January 2013 and was issued to Ben Venue’s chief

RAVICTI used for treating Urea Cycle Disorders (UCD) in patients two years of age and older, is expected to be commercially available by the end of April 2013.

CRLX101, a tumor-targeted nanopharmaceutical, is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1a and releases camptothecin over an extended period of time. The randomized study, which is

The Form 10 Registration Statement includes the significant information about Mallinckrodt and the separation, which contains an overview of the businesses in which Mallinckrodt will operate and of

Under the agreement, MDH will utilize Sectra Breast Imaging PACS to provide remote reading of mammograms to its customers. The agreement also covers Volpara’s integrated breast density software,

Oxtellar XR, a once-daily extended release formulation of oxcarbazepine, is an antiepileptic drug (AED), which is available in 150 mg, 300 mg and 600 mg dosage strengths. The